Adult New Zealand White rabbits were obtained from Bakkon Rabbitry (Viroqua, WI) and housed in the University of Minnesota AALAC-approved animal facility. All procedures were approved by the Animal Care and Use Committee at the University of Minnesota and adhered to the guidelines for use of animals in research prepared by the National Institutes of Health and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Surgical resection of EOMs was performed on 12 normal adult rabbits. The rabbits were anesthetized with an intramuscular injection of ketamine and xylazine (1:1; 10 mg/kg to 2 mg/kg, respectively). One randomly selected superior rectus muscle in each animal was detached from the sclera. A 5- to 6-mm section was removed, and the muscle was sutured to the original insertion using Vicryl 7-0 (polyglactin 910; Ethicon, Somerville, NJ). Because of the size of the resection, the resected segment included both insertional tendon and distal muscle and involved both the orbital and global layers. Although some myofibers would be cut by this method, many myofibers do not run tendon-to-tendon in the EOM. This means that most of the myofibers would not be physically sectioned by this method. The resection resulted in significant muscle stretching in the resected muscle. As is typical of rabbits, minimal rotation of the globe occurred in the surgically treated eyes despite the large resection. As a consequence, there was less substantial stretch of the antagonist inferior rectus muscle than that which was induced in the resected superior rectus muscle. This allowed us to compare the effects of differing amounts of stretch in the same eye. One week after surgery, eight rabbits received intraperitoneal injections of BrdU in sterile saline at a dose of 50 mg/kg body weight. The rabbits received an injection every 2 hours for 12 hours, followed by a 24 hour BrdU-free period. Two weeks after surgery, an additional four rabbits received the same series of BrdU injections. The muscles from four additional normal rabbits labeled similarly with BrdU were also used as control specimens. After the BrdU-free period the rabbits were reanesthetized, and the muscles were prepared for immunohistochemical examination of myonuclei and satellite cells that were positive for BrdU. The superior and inferior rectus muscles were removed from both orbits, embedded in tragacanth gum, and frozen in methylbutane chilled to a slurry on liquid nitrogen. The muscles were serially sectioned at 12 μm. The odd-numbered sections of all the muscles were immunostained for expression of BrdU (1:100; Chemicon, Temecula, CA) and dystrophin (1:20; Novocastra-Vector Laboratories, Burlingame, CA) to ascertain whether the labeled nuclei were within the muscle sarcolemma and therefore were myonuclei. Every 10th even-numbered section was immunostained for both BrdU and laminin (1:20; Sigma-Aldrich, St. Louis, MO), to quantify BrdU-labeled nuclei in the satellite cell position. Every 30th section was stained with hematoxylin and eosin for counting centrally placed nuclei. Of the sections that remained, every second, fourth, sixth, or eighth one was immunostained for one of the following: neonatal myosin, developmental myosin, insulin-like growth factor (IGF)-1, or MyoD. For double-labeling experiments, tissue sections were quenched with hydrogen peroxide, incubated with blocking serum followed by biotin-avidin blocking reagent (Vector Laboratories) and incubated in primary antibody to either dystrophin or laminin. The sections were rinsed in phosphate-buffered saline (PBS), followed by incubation, using the peroxidase ABC kit (Vectastain; Vector Laboratories). The peroxidase was developed with 3,3′-diaminobenzidine (DAB) and hydrogen peroxide without heavy metal intensification. The sections were rinsed in PBS. For the BrdU localization, the sections were incubated in 2 N HCl for 1 hour at 37°C, followed by neutralization in borate buffer and a PBS rinse. The sections were incubated in the primary antibody to BrdU. The sections were rinsed in PBS, incubated using reagents from the alkaline phosphatase ABC kit (Vector Laboratories) and reacted with the alkaline phosphatase black substrate kit. All BrdU myonuclear counts were performed on BrdU-dystrophin–labeled sections. The dystrophin or laminin immunostained brown and the BrdU-positive nuclei were black. BrdU labeling and the number of myofibers were quantified with the aid of a morphometry system (Nova Prime; BioQuant Inc., Nashville, TN).
Immunostaining for visualization of neonatal and developmental myosin heavy chain (MyHC), MyoD, and IGF-1 were performed as described for the dystrophin procedure, except that the antibodies were prepared as follows: neonatal and developmental MyHC at 1:20 (Novocastra-Vector Laboratories), MyoD at 1:25 (Dako Corp., Carpinteria, CA), and IGF-1 at 1:50 (R&D Systems, Minneapolis, MN). Alterations in the expression patterns of the neonatal and developmental myosin heavy chain isoforms, IGF-1, and MyoD in these muscles were examined. The total number of BrdU- or MyoD-labeled nuclei was determined as a percentage of the total number of myofibers in the microscopic fields counted. The percentages of centrally nucleated, neonatal MyHC, developmental MyHC, and MyoD-positive cells were determined as the number positive compared with the number of myofibers counted per cross section. Cross-sectional areas were determined on the BrdU-dystrophin–stained sections by manual tracing of myofibers using morphometry software (Nova Prime; BioQuant). For all measurements, counts and area measurements were made in a minimum of four random fields within both the orbital and global layers of four rectus muscles and four control muscles from a minimum of four rabbits for the resected treated muscles. Sections were chosen to include both the insertional tendon and the midbelly region of the analyzed muscles. In addition, the tissue sections were examined for inflammatory cell infiltrate by using hematoxylin and eosin staining and immunostaining for cd11b (1:10; Serotec, Raleigh, NC), which identified neutrophils, macrophages and lymphocytes. All data are presented as the mean ± SEM.
The percentage positive was compared between the orbital and global layers and analyzed for statistical significance using either an unpaired two-tailed t-test or an analysis of variance (ANOVA) and the Dunn multiple-comparison tests (Prism and Statmate software; GraphPad, San Diego, CA). An F-test was used to verify that the variances were not significantly different. Data were considered significantly different at P < 0.05.
A second set of sections was prepared from both the stretched and control superior rectus muscles in which all the even sections were immunostained with either developmental MyHC or neonatal MyHC. This second set of sections allowed us to determine how many BrdU-positive myonuclei were found within single myofibers and also whether myofibers with BrdU-positive myonuclei were positive or negative for one of the immature myosin heavy chain isoforms. Thus, single myofibers from the rectus muscles were reconstructed from serial cross-sections. A myofiber with a BrdU-positive myonucleus was located. These were selected to be randomly located in the muscle length and cross-section. The locations of BrdU-positive myonuclei and BrdU-positive satellite cells and whether the fiber was positive or negative for expression of developmental or neonatal MyHC were recorded along the length of each reconstructed myofiber by using morphology analysis software (Nova Prime; BioQuant). Three-dimensional reconstructions were built in a second program (Topographer Program; BioQuant).
Western blot analysis were performed on the nuclear fraction obtained from resected and normal EOMs. The muscles were weighed and homogenized with buffer from a kit (Buffer C; Compartmental Protein Extraction Kit; Chemicon). The samples were spun at 110,000 rpm for 20 minutes at 4°C. The pellets were placed in buffer W and spun a second time at 110,000 rpm for 20 minutes at 4°C. The pellets were placed in buffer N, rotated, and spun again as just described. Aliquots of the supernatant containing nuclear proteins were removed to determine protein concentration using the bicinchoninic acid (BCA) assay (Pierce Biotechnology, Rockford, IL). Nuclear proteins were separated on 4% to 20% Tris-HCl mini-gels (Bio-Rad, Hercules, CA) run at 120 V. After approximately 1 hour, the gels were removed into 80% Tris, glycine, SDS transfer buffer and 20% methanol and transferred onto nitrocellulose membranes at 350 mA for approximately 1 hour. Duplicate gels with the same amount of protein loaded were run and stained with Coomassie blue solution to monitor consistency in protein loading. The nitrocellulose membranes were placed overnight into blocking solution consisting of 0.015% NaN3, 1× Tris–buffered saline (TBS) and 20% goat serum. The membranes were incubated with a primary antibody to MyoD (1:200, Santa Cruz Biotechnology, Santa Cruz, CA), washed three times in TBS containing 0.05% Tween-20, and incubated in secondary antibody at a 1:1000 dilution (Sigma-Aldrich). They were washed again and reacted with a reaction substrate consisting of the 5-bromo-4-chloro-3-indoyl phosphate/nitroblue tetrazolium (BCIP/NBT) substrate system for membranes (B3804; Sigma-Aldrich). To determine the relative content of MyoD in the immunoblots, densitometric analysis was performed (SigmaScan; SPSS Science, Chicago, IL). Preliminary experiments determined that 1 to 20 μg of protein produced a linear signal. Thus, 10 μg protein was used to load the gels for semiquantitative Western blot analysis. All lanes were compared to a lane of purified MyoD protein (Santa Cruz Biotechnology) included in each Western blot.